KBI-BIOPHARMA
6.7.2022 13:47:10 CEST | Business Wire | Press release
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/
As demand for innovative biologics and effective biosimilars to treat cancer, infectious diseases, and autoimmune diseases continue to rise in Europe and around the world, developing and manufacturing these and other therapeutics, remains complex and time-consuming. By co-locating in one facility, KBI and Selexis will deliver trusted, streamlined, and cost-effective solutions to help clients confidently advance their investigational therapies.
“The opening of our Geneva facility last month was a major milestone for KBI and Selexis, and we are excited to come together today and commemorate this great achievement,” said Mark W. Womack, CEO of KBI and Selexis. “KBI and Selexis have a long history of success together. Our collaboration has accelerated more than 60 drug development programs in Europe and worldwide. Integrating Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience provides our clients with seamless, cost-effective, and reliable development and manufacturing for their products. Our aim has always been to help our clients bring novel and effective therapies to the clinic and the market faster. This facility will help advance that mission.”
The ~94,000 square-foot facility will house new laboratories to support Selexis’ unique technical cell line workflows and KBI’s process development and cGMP manufacturing and quality control with a suite of analytical testing laboratories and cGMP single-use manufacturing trains. The expansion will generate over 300 positions in development, operations, and quality assurance. The ribbon-cutting, held on July 5, was attended by the following:
- Luca Bolliger, VP of the Swiss Biotech Association and President of the Swiss Biotech Success Stories Jury
- Mario Rodriguez, Mayor of Plan-les-Ouates
- Fabienne Fischer, State Councilor - Member of the Geneva government, Head of the economy and employment department (DEE)
“I am delighted with the development of KBI and Selexis' activities in Geneva, which contributes to the development of the life sciences sector in Geneva and reinforces our local ecosystem,” said Councilor Fischer. “It also demonstrates the potential and attractiveness of our region.”
About KBI Biopharma, Inc.
KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences company. KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global client partners have utilized Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005082/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microsoft and Postel: An Innovative New Data and AI-Driven Solution to Optimize Italian SMEs' Relationships with Their Customers28.4.2026 07:00:00 CEST | Press release
Microsoft and Postel, a Poste Italiane Group company, announce an evolution of their collaboration and of the agreements they have signed for the digitalization of Italian businesses, welcoming Audiencerate as technology partner in the Data and Direct & Digital Marketing space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427013396/en/ The Marketing Data Platform combines AI-powered market intelligence, first-party data and omnichannel activation to help SMEs analyze market trends and historical campaign performance, turning insights into audiences and increasingly targeted future actions. The agreement provides for the distribution of an integrated platform that combines Postel's omnichannel physical-and-digital communication capabilities with Audiencerate'sdata intelligence functionalities and Microsoft's AI and Cloud solutions. The solution enables SMEs to leverage and activate their own data across the entire custom
LTM Launches BlueVerse™ Studio as a Hub for Enterprise Agentic AI Adoption28.4.2026 07:00:00 CEST | Press release
Showcasing AI capabilities to solve real‑world client challenges LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of its BlueVerse Studio in Bengaluru, a hub designed to accelerate Enterprise Agentic AI adoption for clients and deliver measurable business outcomes. LTM continues to launch more studios globally to drive AI innovation and also has studios in London and Mumbai. As part of the company’s ongoing investment in bringing innovation closer to clients, the BlueVerse Studio was created to help clients scale AI solutions from experiments to practical applications while ensuring trust and control. It unites LTM’s strongest AI capabilities, including BlueVerse CraftStudio, physical AI showcases, and industry-centric AI offerings, within one ecosystem along with: Multiple BlueVerse-certified consulting and delivery professionals currently support enterprise-grade AI solutions. These certifications provide expertise in developing inte
Helical Fusion Launches Helix Program “Official Partners” to Build Japan’s Industrial Coalition for Commercial Fusion Energy28.4.2026 05:00:00 CEST | Press release
Multiple long-established Japanese companies join as inaugural partners in a shared push to build the fusion energy industry; Helical Fusion also completed the first close of its Series B round Helical Fusion Co., Ltd., a fusion energy company developing a Helical stellarator power plant, today announced the launch of Helix Program Official Partners, a new strategic partnership framework designed to bring together long-term industrial collaborators committed to advancing fusion from laboratory progress to real-world fusion power deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427596284/en/ Helical Fusion’s Integrated Demonstration Device, “Helix HARUKA,” currently under construction (photographed at the company’s dedicated workspace within the National Institute for Fusion Science in Gifu, Japan) The Helix Program is Helical Fusion’s core initiative to realize commercially viable fusion energy in the 2030s. Rat
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom